Fig. 3

Morphometric analyses of β cells and immune cells in IDDM rats after anti-TCR combination therapies. Changes in the rate of a proliferation, b apoptosis, c islet infiltration score and d pancreatic β cell mass after successful anti-TCR combination therapy with anti-IL-6 or anti-IL-17A alone or combined together after diabetes manifestation. Measurements were performed immediately before therapy (first biopsy), at the end of therapy (second biopsy) and 60 days after the end of therapy Data are mean values ± SEM. Comparison of the different experimental groups by one-way ANOVA followed by Bonferroni test ***p < 0.001, **p < 0.01 and *p < 0.05 to the healthy control, ^$$$p < 0.001 to anti-TCR combination with anti-IL-6, ^§§§p < 0.001 and ^§§p < 0.01 to anti-TCR combination with anti-IL-17A, ^###p < 0.001 and ^##p < 0.01 to triple combination for each observation time point. Numbers of pancreases analysed as given in Fig. 1